HB1691: Ensuring Patient Access to Critical Breakthrough Products Act of 2023

Introduced in House

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Referred to the Subcommittee on Health.

Subcommittee Consideration and Mark-up Session Held

Forwarded by Subcommittee to Full Committee by the Yeas and Nays: 21 - 6.

Committee Consideration and Mark-up Session Held

Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 36 - 5.